FLT3/Flk-2 hFc Chimera, Cynomolgus
FLT3/Flk-2 HFc Chimera, Cynomolgus

Immobilized Human FLT3 Ligand, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for FLT3/Flk-2 hFc Chimera, Cynomolgus, hFc Tag with the EC50 of 13.6 ng/ml determined by ELISA.

FLT3/Flk-2 HFc Chimera, Cynomolgus

FLT3/Flk-2 hFc Chimera, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

FLT3/Flk-2 hFc Chimera, Cynomolgus

The Flt-3 (fms-like tyrosine kinase) receptor, also named Flk-2 (fetal liver kinase) and Stk-1(stem cell tyrosine kinase) is a member of the class III subfamily of receptor tyrosine kinases that also includes KIT, the receptor for SCF and FMS, the receptor for M-CSF. Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1.
Z04793
¥72,752.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
FLT3/Flk-2 (Gln28-Ser541)
Accession # A0A2K5VQ48		 hFc
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 84.58 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 160-180 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • FLT3/Flk-2 HFc Chimera, Cynomolgus
    • FLT3/Flk-2 HFc Chimera, Cynomolgus

    Immobilized Human FLT3 Ligand, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for FLT3/Flk-2 hFc Chimera, Cynomolgus, hFc Tag with the EC50 of 13.6 ng/ml determined by ELISA.

  • FLT3/Flk-2 HFc Chimera, Cynomolgus
    • FLT3/Flk-2 HFc Chimera, Cynomolgus

    FLT3/Flk-2 hFc Chimera, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background The Flt-3 (fms-like tyrosine kinase) receptor, also named Flk-2 (fetal liver kinase) and Stk-1(stem cell tyrosine kinase) is a member of the class III subfamily of receptor tyrosine kinases that also includes KIT, the receptor for SCF and FMS, the receptor for M-CSF. Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1.
Synonyms CD135; FLK2; STK-1; FLT-3

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.